Reproduktive Faktoren und das Ovarialkarzinomrisiko

Susanne Schüler-Toprak; Olaf Ortmann

doi:10.1055/a-1098-0234

Frauenheilkunde up2date, Inhaltsverzeichnis

Frauenheilkunde up2date 2021; 15(01): 43-61
DOI: 10.1055/a-1098-0234

Gynäkologische Onkologie

Reproduktive Faktoren und das Ovarialkarzinomrisiko

Susanne Schüler-Toprak

,

Olaf Ortmann

Abstract

Alle Artikel dieser Rubrik

Trotz intensiver wissenschaftlicher Bemühungen handelt es sich beim Ovarialkarzinom um das gynäkologische Malignom mit der höchsten Mortalität. Parität, Laktation, aber auch das Alter bei Menarche und Menopause beeinflussen das Risiko, an einem Ovarialkarzinom zu erkranken. Dieser Artikel vermittelt einen Überblick über den Einfluss dieser reproduktiven Faktoren auf das Ovarialkarzinomrisiko entsprechend dem aktuellen Stand der Wissenschaft.

Schlüsselwörter

Ovarialkarzinom - Risikofaktoren - reproduktive Faktoren - Parität - Laktation

Volltext

Referenzen

Literatur
1 Deutsche Krebsgesellschaft DK, AWMF. Leitlinienprogramm Onkologie. S3-Leitlinie Diagnostik, Therapie und Nachsorge maligner Ovarialtumoren. Im Internet (Stand: 02.05.2020): https://www.leitlinienprogramm-onkologie.de/leitlinien/ovarialkarzinom/
2 Kurman RJ, Shih Ie M. The dualistic model of ovarian carcinogenesis: Revisited, revised, and expanded. Am J Pathol 2016; 186: 733-747
3 Shvartsman HS, Sun CC, Bodurka DC. et al. Comparison of the clinical behavior of newly diagnosed stages II–IV low-grade serous carcinoma of the ovary with that of serous ovarian tumors of low malignant potential that recur as low-grade serous carcinoma. Gynecol Oncol 2007; 105: 625-629
4 Grisham RN, Iyer G, Garg K. et al. BRAF mutation is associated with early stage disease and improved outcome in patients with low-grade serous ovarian cancer. Cancer 2013; 119: 548-554
5 Langdon SP, Gourley C, Gabra H. et al. Endocrine therapy in epithelial ovarian cancer. Expert Rev Anticancer Ther 2017; 17: 109-117
6 Sieh W, Kobel M, Longacre TA. et al. Hormone-receptor expression and ovarian cancer survival: an Ovarian Tumor Tissue Analysis consortium study. Lancet Oncol 2013; 14: 853-862
7 Gershenson DM, Bodurka DC, Coleman RL. et al. Hormonal maintenance therapy for women with low-grade serous cancer of the ovary or peritoneum. J Clin Oncol 2017; 35: 1103-1111
8 Vang R, Levine DA, Soslow RA. et al. Molecular alterations of tp53 are a defining feature of ovarian high-grade serous carcinoma: A rereview of cases lacking tp53 mutations in The Cancer Genome Atlas Ovarian Study. Int J Gynecol Pathol 2016; 35: 48-55
9 [Anonym] Integrated genomic analyses of ovarian carcinoma. Nature 2011; 474: 609-615
10 Hart WR. Mucinous tumors of the ovary: a review. Int J Gynecol Pathol 2005; 24: 4-25
11 Mok SC, Bell DA, Knapp RC. et al. Mutation of K-ras protooncogene in human ovarian epithelial tumors of borderline malignancy. Cancer Res 1993; 53: 1489-1492
12 Wu CH, Mao TL, Vang R. et al. Endocervical-type mucinous borderline tumors are related to endometrioid tumors based on mutation and loss of expression of ARID1A. Int J Gynecol Pathol 2012; 31: 297-303
13 Vercellini P, Vigano P, Buggio L. et al. Perimenopausal management of ovarian endometriosis and associated cancer risk: When is medical or surgical treatment indicated?. Best Pract Res Clin Obstet Gynaecol 2018; 51: 151-168
14 Guan B, Rahmanto YS, Wu RC. et al. Roles of deletion of Arid1a, a tumor suppressor, in mouse ovarian tumorigenesis. J Natl Cancer Inst 2014; 106
15 Chandler RL, Damrauer JS, Raab JR. et al. Coexistent ARID1A-PIK3CA mutations promote ovarian clear-cell tumorigenesis through pro-tumorigenic inflammatory cytokine signalling. Nat Commun 2015; 6: 6118
16 Yamaguchi K, Huang Z, Matsumura N. et al. Epigenetic determinants of ovarian clear cell carcinoma biology. Int J Cancer 2014; 135: 585-597
17 Kurman RJ, Shih Ie M. Molecular pathogenesis and extraovarian origin of epithelial ovarian cancer-shifting the paradigm. Hum Pathol 2011; 42: 918-931
18 Prowse AH, Manek S, Varma R. et al. Molecular genetic evidence that endometriosis is a precursor of ovarian cancer. Int J Cancer 2006; 119: 556-562
19 Emons G, Pahwa GS, Brack C. et al. Gonadotropin releasing hormone binding sites in human epithelial ovarian carcinomata. Eur J Cancer Clin Oncol 1989; 25: 215-221
20 Grundker C, Emons G. The role of gonadotropin-releasing hormone in cancer cell proliferation and metastasis. Front Endocrinol (Lausanne) 2017; 8: 187
21 Grundker C, Gunthert AR, Millar RP. et al. Expression of gonadotropin-releasing hormone II (GnRH-II) receptor in human endometrial and ovarian cancer cells and effects of GnRH-II on tumor cell proliferation. J Clin Endocrinol Metab 2002; 87: 1427-1430
22 Lu JJ, Zheng Y, Kang X. et al. Decreased luteinizing hormone receptor mRNA expression in human ovarian epithelial cancer. Gynecol Oncol 2000; 79: 158-168
23 Chudecka-Glaz A, Rzepka-Gorska I, Kosmowska B. Gonadotropin (LH, FSH) levels in serum and cyst fluid in epithelial tumors of the ovary. Arch Gynecol Obstet 2004; 270: 151-156
24 Irvin SR, Weiderpass E, Stanczyk FZ. et al. Association of anti-mullerian hormone, follicle-stimulating hormone, and inhibin B with risk of ovarian cancer in the Janus Serum Bank. Cancer Epidemiol Biomarkers Prev 2020; 29: 636-642
25 Choi JH, Choi KC, Auersperg N. et al. Overexpression of follicle-stimulating hormone receptor activates oncogenic pathways in preneoplastic ovarian surface epithelial cells. J Clin Endocrinol Metab 2004; 89: 5508-5516
26 Tashiro H, Katabuchi H, Begum M. et al. Roles of luteinizing hormone/chorionic gonadotropin receptor in anchorage-dependent and -independent growth in human ovarian surface epithelial cell lines. Cancer Sci 2003; 94: 953-959
27 Ji Q, Liu PI, Chen PK. et al. Follicle stimulating hormone-induced growth promotion and gene expression profiles on ovarian surface epithelial cells. Int J Cancer 2004; 112: 803-814
28 Lau MT, Wong AS, Leung PC. Gonadotropins induce tumor cell migration and invasion by increasing cyclooxygenases expression and prostaglandin E(2) production in human ovarian cancer cells. Endocrinology 2010; 151: 2985-2993
29 Schiffenbauer YS, Meir G, Maoz M. et al. Gonadotropin stimulation of MLS human epithelial ovarian carcinoma cells augments cell adhesion mediated by CD44 and by alpha(v)-integrin. Gynecol Oncol 2002; 84: 296-302
30 Zygmunt M, Herr F, Keller-Schoenwetter S. et al. Characterization of human chorionic gonadotropin as a novel angiogenic factor. J Clin Endocrinol Metab 2002; 87: 5290-5296
31 Heinonen PK, Koivula T, Rajaniemi H. et al. Peripheral and ovarian venous concentrations of steroid and gonadotropin hormones in postmenopausal women with epithelial ovarian tumors. Gynecol Oncol 1986; 25: 1-10
32 Cunat S, Rabenoelina F, Daures JP. et al. Aromatase expression in ovarian epithelial cancers. J Steroid Biochem Mol Biol 2005; 93: 15-24
33 Trabert B, Brinton LA, Anderson GL. et al. Circulating estrogens and postmenopausal ovarian cancer risk in the Womenʼs Health Initiative Observational Study. Cancer Epidemiol Biomarkers Prev 2016; 25: 648-656
34 Vuong NH, Cook DP, Forrest LA. et al. Single-cell RNA-sequencing reveals transcriptional dynamics of estrogen-induced dysplasia in the ovarian surface epithelium. PLoS Genet 2018; 14: e1007788
35 Valladares M, Plaza-Parrochia F, Lepez M. et al. Effect of estradiol on the expression of angiogenic factors in epithelial ovarian cancer. Histol Histopathol 2017; 32: 1187-1196
36 Schuler-Toprak S, Weber F, Skrzypczak M. et al. Estrogen receptor beta is associated with expression of cancer associated genes and survival in ovarian cancer. BMC Cancer 2018; 18: 981
37 Lee P, Rosen DG, Zhu C. et al. Expression of progesterone receptor is a favorable prognostic marker in ovarian cancer. Gynecologic Oncol 2005; 96: 671-677
38 Lenhard M, Tereza L, Heublein S. et al. Steroid hormone receptor expression in ovarian cancer: progesterone receptor B as prognostic marker for patient survival. BMC Cancer 2012; 12: 553
39 Treeck O, Pfeiler G, Mitter D. et al. Estrogen receptor {beta}1 exerts antitumoral effects on SK-OV-3 ovarian cancer cells. J Endocrinol 2007; 193: 421-433
40 Schuler-Toprak S, Moehle C, Skrzypczak M. et al. Effect of estrogen receptor beta agonists on proliferation and gene expression of ovarian cancer cells. BMC Cancer 2017; 17: 319
41 Matsumura S, Ohta T, Yamanouchi K. et al. Activation of estrogen receptor alpha by estradiol and cisplatin induces platinum-resistance in ovarian cancer cells. Cancer Biol Ther 2017; 18: 730-739
42 Syed V, Mukherjee K, Godoy-Tundidor S. et al. Progesterone induces apoptosis in TRAIL-resistant ovarian cancer cells by circumventing c-FLIPL overexpression. J Cell Biochem 2007; 102: 442-452
43 Hua K, Feng W, Cao Q. et al. Estrogen and progestin regulate metastasis through the PI3K/AKT pathway in human ovarian cancer. Int J Oncol 2008; 33: 959-967
44 Zhao D, Zhang F, Zhang W. et al. Prognostic role of hormone receptors in ovarian cancer: a systematic review and meta-analysis. Int J Gynecol Cancer 2013; 23: 25-33
45 Cardillo MR, Petrangeli E, Aliotta N. et al. Androgen receptors in ovarian tumors: correlation with oestrogen and progesterone receptors in an immunohistochemical and semiquantitative image analysis study. J Exp Clin Cancer Res 1998; 17: 231-237
46 Edmondson RJ, Monaghan JM, Davies BR. The human ovarian surface epithelium is an androgen responsive tissue. Br J Cancer 2002; 86: 879-885
47 Giovannucci E, Stampfer MJ, Krithivas K. et al. The CAG repeat within the androgen receptor gene and its relationship to prostate cancer. Proc Natl Acad Sci U S A 1997; 94: 3320-3323
48 Li AJ, Elmore RG, Pavelka JC. et al. Hyperandrogenism, mediated by obesity and receptor polymorphisms, promotes aggressive epithelial ovarian cancer biology. Gynecol Oncol 2007; 107: 420-423
49 Evangelou A, Jindal SK, Brown TJ. et al. Down-regulation of transforming growth factor beta receptors by androgen in ovarian cancer cells. Cancer Res 2000; 60: 929-935
50 Sheach LA, Adeney EM, Kucukmetin A. et al. Androgen-related expression of G-proteins in ovarian cancer. Br J Cancer 2009; 101: 498-503
51 Ilekis JV, Connor JP, Prins GS. et al. Expression of epidermal growth factor and androgen receptors in ovarian cancer. Gynecol Oncol 1997; 66: 250-254
52 Fathalla MF. Incessant ovulation-a factor in ovarian neoplasia?. Lancet 1971; 2: 163
53 Kuhn E, Kurman RJ, Shih IM. Ovarian Cancer Is an Imported Disease: Fact or Fiction?. Curr Obstet Gynecol Rep 2012; 1: 1-9
54 Emons G. Hormonelle Kontrazeption und Krebs. Frauenheilkunde up2date 2020; 14: 243-255
55 Cramer DW, Welch WR. Determinants of ovarian cancer risk. II. Inferences regarding pathogenesis. J Natl Cancer Inst 1983; 71: 717-721
56 Blaakaer J, Baeksted M, Micic S. et al. Gonadotropin-releasing hormone agonist suppression of ovarian tumorigenesis in mice of the Wx/Wv genotype. Biol Reprod 1995; 53: 775-779
57 Risch HA. Hormonal etiology of epithelial ovarian cancer, with a hypothesis concerning the role of androgens and progesterone. J Natl Cancer Inst 1998; 90: 1774-1786
58 Helzlsouer KJ, Alberg AJ, Gordon GB. et al. Serum gonadotropins and steroid hormones and the development of ovarian cancer. JAMA 1995; 274: 1926-1930
59 Wynder EL, Dodo H, Barber HR. Epidemiology of cancer of the ovary. Cancer 1969; 23: 352-370
60 Sonnichsen AC, Lindlacher U, Richter WO. et al. [Obesity, body fat distribution and the incidence of breast, cervical, endometrial and ovarian carcinomas]. Dtsch Med Wochenschr 1990; 115: 1906-1910
61 [Anonym] Ovarian cancer and body size: individual participant meta-analysis including 25,157 women with ovarian cancer from 47 epidemiological studies. PLoS Med 2012; 9: e1001200
62 Olsen CM, Green AC, Nagle CM. et al. Epithelial ovarian cancer: testing the ʼandrogens hypothesisʼ. Endocr Relat Cancer 2008; 15: 1061-1068
63 Massuger L, Roelofsen T, Ham M. et al. The origin of serous ovarian cancer may be found in the uterus: a novel hypothesis. Med Hypotheses 2010; 74: 859-861
64 Baergen RN, Warren CD, Isacson C. et al. Early uterine serous carcinoma: clonal origin of extrauterine disease. Int J Gynecol Pathol 2001; 20: 214-219
65 Kupryjanczyk J, Thor AD, Beauchamp R. et al. Ovarian, peritoneal, and endometrial serous carcinoma: clonal origin of multifocal disease. Mod Pathol 1996; 9: 166-173
66 Reid BM, Permuth JB, Sellers TA. Epidemiology of ovarian cancer: a review. Cancer Biol Med 2017; 14: 9-32
67 Besevic J, Gunter MJ, Fortner RT. et al. Reproductive factors and epithelial ovarian cancer survival in the EPIC cohort study. Br Journal Cancer 2015; 113: 1622-1631
68 Tzonou A, Day NE, Trichopoulos D. et al. The epidemiology of ovarian cancer in Greece: a case-control study. Eur J Cancer Clin Oncol 1984; 20: 1045-1052
69 Shafrir AL, Babic A, Tamimi RM. et al. Reproductive and hormonal factors in relation to survival and platinum resistance among ovarian cancer cases. Br J Cancer 2016; 115: 1391-1399
70 Tsilidis KK, Allen NE, Key TJ. et al. Oral contraceptive use and reproductive factors and risk of ovarian cancer in the European Prospective Investigation into Cancer and Nutrition. Br J Cancer 2011; 105: 1436-1442
71 Wentzensen N, Poole EM, Trabert B. et al. Ovarian cancer risk factors by histologic subtype: An analysis from the Ovarian Cancer Cohort Consortium. J Clin Oncol 2016; 34: 2888-2898
72 Braem MG, Onland-Moret NC, van den Brandt PA. et al. Reproductive and hormonal factors in association with ovarian cancer in the Netherlands cohort study. Am J Epidemiol 2010; 172: 1181-1189
73 Trabert B, Tworoger SS, OʼBrien KM. et al. The risk of ovarian cancer increases with an increase in the lifetime number of ovulatory cycles: An analysis from the Ovarian Cancer Cohort Consortium (OC3). Cancer Res 2020; 80: 1210-1218
74 Peres LC, Moorman PG, Alberg AJ. et al. Lifetime number of ovulatory cycles and epithelial ovarian cancer risk in African American women. Cancer Causes Control 2017; 28: 405-414
75 Kim SJ, Rosen B, Fan I. et al. Epidemiologic factors that predict long-term survival following a diagnosis of epithelial ovarian cancer. Br J Cancer 2017; 116: 964-971
76 Modugno F, Goughnour SL, Wallack D. et al. Breastfeeding factors and risk of epithelial ovarian cancer. Gynecol Oncol 2019; 153: 116-122
77 Gaitskell K, Green J, Pirie K. et al. Histological subtypes of ovarian cancer associated with parity and breastfeeding in the prospective Million Women Study. Int J Cancer 2018; 142: 281-289
78 Moorman PG, Alberg AJ, Bandera EV. et al. Reproductive factors and ovarian cancer risk in African-American women. Ann Epidemiol 2016; 26: 654-662
79 Jordan SJ, Cushing-Haugen KL, Wicklund KG. et al. Breast-feeding and risk of epithelial ovarian cancer. Cancer Causes Control 2012; 23: 919-927
80 Jordan SJ, Siskind V, Green AC. et al. Breastfeeding and risk of epithelial ovarian cancer. Cancer Causes Control 2010; 21: 109-116
81 Troisi R, Bjorge T, Gissler M. et al. The role of pregnancy, perinatal factors and hormones in maternal cancer risk: a review of the evidence. J Intern Med 2018; 283: 430-445
82 Whittemore AS, Harris R, Itnyre J. Characteristics relating to ovarian cancer risk: collaborative analysis of 12 US case-control studies. II. Invasive epithelial ovarian cancers in white women. Collaborative Ovarian Cancer Group. Am J Epidemiol 1992; 136: 1184-1203
83 Paltiel O, Tajuddin SM, Polanker Y. et al. Grand multiparity and reproductive cancer in the Jerusalem Perinatal Study Cohort. Cancer Causes Control 2016; 27: 237-247
84 McGuire V, Hartge P, Liao LM. et al. Parity and oral contraceptive use in relation to ovarian cancer risk in older women. Cancer Epidemiol Biomarkers Prev 2016; 25: 1059-1063
85 Skold C, Bjorge T, Ekbom A. et al. Preterm delivery is associated with an increased risk of epithelial ovarian cancer among parous women. Int J Cancer 2018; 143: 1858-1867
86 Wu AH, Pearce CL, Lee AW. et al. Timing of births and oral contraceptive use influences ovarian cancer risk. Int J Cancer 2017; 141: 2392-2399
87 Fortner RT, Ose J, Merritt MA. et al. Reproductive and hormone-related risk factors for epithelial ovarian cancer by histologic pathways, invasiveness and histologic subtypes: Results from the EPIC cohort. Int J Cancer 2015; 137: 1196-1208
88 Brinton LA, Melton LJ, Malkasian GD. et al. Cancer risk after evaluation for infertility. Am J Epidemiol 1989; 129: 712-722
89 Rodriguez C, Tatham LM, Calle EE. et al. Infertility and risk of fatal ovarian cancer in a prospective cohort of US women. Cancer Causes Control 1998; 9: 645-651
90 Stentz NC, Koelper N, Barnhart KT. et al. Infertility and mortality. Am J Obstet Gynecol 2020; 222: 251.e1-251.e10
91 Rossing MA, Tang MT, Flagg EW. et al. A case-control study of ovarian cancer in relation to infertility and the use of ovulation-inducing drugs. Am J Epidemiol 2004; 160: 1070-1078
92 Lundberg FE, Iliadou AN, Rodriguez-Wallberg K. et al. The risk of breast and gynecological cancer in women with a diagnosis of infertility: a nationwide population-based study. Eur J Epidemiol 2019; 34: 499-507
93 Venn A, Watson L, Bruinsma F. et al. Risk of cancer after use of fertility drugs with in-vitro fertilisation. Lancet 1999; 354: 1586-1590
94 Ness RB, Cramer DW, Goodman MT. et al. Infertility, fertility drugs, and ovarian cancer: a pooled analysis of case-control studies. Am J Epidemiol 2002; 155: 217-224
95 Pearce CL, Templeman C, Rossing MA. et al. Association between endometriosis and risk of histological subtypes of ovarian cancer: a pooled analysis of case-control studies. Lancet Oncol 2012; 13: 385-394
96 Jensen A, Sharif H, Olsen JH. et al. Risk of breast cancer and gynecologic cancers in a large population of nearly 50,000 infertile Danish women. Am J Epidemiol 2008; 168: 49-57
97 Stewart LM, Spilsbury K, Jordan S. et al. Risk of high-grade serous ovarian cancer associated with pelvic inflammatory disease, parity and breast cancer. Cancer Epidemiol 2018; 55: 110-116
98 Jiao J, Sagnelli M, Shi B. et al. Genetic and epigenetic characteristics in ovarian tissues from polycystic ovary syndrome patients with irregular menstruation resemble those of ovarian cancer. BMC Endocr Disord 2019; 19: 30
99 Schildkraut JM, Schwingl PJ, Bastos E. et al. Epithelial ovarian cancer risk among women with polycystic ovary syndrome. Obstet Gynecol 1996; 88: 554-559
100 Chittenden BG, Fullerton G, Maheshwari A. et al. Polycystic ovary syndrome and the risk of gynaecological cancer: a systematic review. Reprod Biomed Online 2009; 19: 398-405
101 Barry JA, Azizia MM, Hardiman PJ. Risk of endometrial, ovarian and breast cancer in women with polycystic ovary syndrome: a systematic review and meta-analysis. Human Reproduction Update 2014; 20: 748-758
102 Ding DC, Chen W, Wang JH. et al. Association between polycystic ovarian syndrome and endometrial, ovarian, and breast cancer: A population-based cohort study in Taiwan. Medicine (Baltimore) 2018; 97: e12608
103 Rebar R, Judd HL, Yen SS. et al. Characterization of the inappropriate gonadotropin secretion in polycystic ovary syndrome. J Clin Invest 1976; 57: 1320-1329
104 Baird DT, Corker CS, Davidson DW. et al. Pituitary-ovarian relationships in polycystic ovary syndrome. J Clin Endocrinol Metab 1977; 45: 798-801
105 Kurman RJ. ed. WHO Classification of Tumors of female reproductive Organs. Lyon: IARC; 2014